Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
REGROTON is an oral tablet NDA approved in 1964 by Sanofi with an unknown mechanism of action and indication profile. The drug's mechanism and therapeutic class remain unspecified in available data. Patient population and clinical use cannot be determined without additional information.
Product approaching loss of exclusivity with moderate competitive pressure (30%) suggests contracting team and transition-focused roles in final years of market protection.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
REGROTON offers limited career growth with zero linked job postings and approaching loss of exclusivity. Opportunities center on defensive brand management, generic preparation, and sales force optimization rather than expansion or innovation.
Worked on REGROTON at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.